Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Cancer Invest ; 40(5): 425-436, 2022 May.
Article in English | MEDLINE | ID: mdl-35225723

ABSTRACT

Radiotherapy is one of the major approaches to cancer treatment. Artificial intelligence in radiotherapy (shortly, Intelligent radiotherapy) mainly involves big data, deep learning, extended reality, digital twin, radiomics, Internet plus and Internet of Things (IoT), which establish an automatic and intelligent network platform consisting of radiotherapy preparation, target volume delineation, treatment planning, radiation delivery, quality assurance (QA) and quality control (QC), prognosis judgment and post-treatment follow-up. Intelligent radiotherapy is an interdisciplinary frontier discipline in infancy. The review aims to summary the important implements of intelligent radiotherapy in various areas and put forward the future of unmanned radiotherapy center.


Subject(s)
Artificial Intelligence , Intelligence , Humans , Prognosis
3.
Cancer Med ; 9(10): 3437-3444, 2020 05.
Article in English | MEDLINE | ID: mdl-32207253

ABSTRACT

There were no ideal markers to predict the development of radiation pneumonitis (RP). We want to investigate the value of variations of lymphocytes and T lymphocyte subsets in predicting RP after radiotherapy (RT) of lung cancer based on previous clinical findings. A total of 182 lung cancer patients who received RT were retrospectively analyzed. Circulating lymphocytes and T lymphocyte subsets were measured before, during, and after RT. Patients were evaluated from the start of RT to 6 months post-RT. A mice model with acute radiation-induced lung injury was established and circulating lymphocytes were measured weekly until 8 weeks after irradiation. Univariate and multivariate analyses were adopted to identify risk factors of RP. Lymphocyte levels significantly decreased (P < .001) in patients before RP symptoms developed that also was able to be seen in the mice model and the values recovered during remission of symptoms. The decrease in lymphocyte count reflected the severity of RP. Meanwhile, CD4+  T lymphocyte count was significantly lower during the occurrence of symptoms in patients with RP than in those without RP (P < .001), and it improved along with RP recovery. Levels of lymphocytes and CD4+  T lymphocyte subsets proved as independent predictors of RP. Here we showed that lower peripheral blood levels of lymphocytes and CD4+  T lymphocyte were associated with an increased risk of RP, which was validated by this mice model, and thus are associated with differences in radiation-induced lung toxicity among individuals and help identify those who are susceptible to developing RP after RT.


Subject(s)
Adenocarcinoma of Lung/radiotherapy , Carcinoma, Squamous Cell/radiotherapy , Lung Neoplasms/radiotherapy , Lung/radiation effects , Radiation Pneumonitis/blood , Radiotherapy, Intensity-Modulated/adverse effects , Small Cell Lung Carcinoma/radiotherapy , T-Lymphocyte Subsets , T-Lymphocytes , Adenocarcinoma of Lung/pathology , Adult , Aged , Aged, 80 and over , Animals , CD4 Lymphocyte Count , Carcinoma, Squamous Cell/pathology , Female , Humans , Leukocyte Count , Lung Neoplasms/pathology , Lymphocyte Count , Male , Mice , Middle Aged , Neutrophils , Retrospective Studies , Small Cell Lung Carcinoma/pathology
4.
Radiat Oncol ; 14(1): 104, 2019 Jun 13.
Article in English | MEDLINE | ID: mdl-31196126

ABSTRACT

PURPOSE: Despite recent advances in multimodal treatments, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM. MATERIALS AND METHODS: From February 2012 to February 2018, 80 patients with newly diagnosed and histologically confirmed GBM in our institute were reviewed retrospectively. All patients underwent complete resection or partial resection surgery and then received hypofractionated SIB-IMRT with concomitant TMZ followed by adjuvant TMZ. A total dose of 64 Gy over 27 fractions was delivered to the gross tumor volume (GTV), clinical target volume 1 (CTV1) received 60 Gy over 27 fractions, and CTV2 received 54 Gy over 27 fractions. The progression-free survival (PFS) and overall survival (OS) rates and the toxicities were evaluated. Prognostic factors were analyzed using univariate and multivariate Cox models. RESULTS: The median follow-up was 16 months (range, 5~72 months). The median PFS was 15 months, and the 1-, 2-, and 3-year PFS rates were 56.0, 27.6, and 19.5%, respectively. The median OS was 21 months, and the 1-, 2-, 3-, and 5-year OS rates were 77.6, 41.6, 32.8, and 13.4%, respectively. The toxicities were mild and acceptable. Age, KPS scores and the total number of TMZ cycles were significant factors influencing patient survival. CONCLUSION: Moderately hypofractionated SIB-IMRT combined with TMZ is a feasible and safe treatment option with mild toxicity and good PFS and OS.


Subject(s)
Brain Neoplasms/therapy , Chemoradiotherapy/methods , Glioblastoma/therapy , Postoperative Care , Radiotherapy, Intensity-Modulated/methods , Temozolomide/therapeutic use , Adult , Aged , Antineoplastic Agents, Alkylating/therapeutic use , Brain Neoplasms/pathology , Female , Glioblastoma/pathology , Humans , Male , Middle Aged , Prognosis , Radiation Dose Hypofractionation , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Retrospective Studies , Survival Rate , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...